# Celltrion clinical trials: 77 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 77 trials with Celltrion as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Celltrion: 77 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/celltrion

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 77
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 77, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 16, 2026 | NCT07533539 | Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of L03TD1 in... | Celltrion | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533539) |
| January 26, 2026 | NCT07367958 | A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects | Celltrion | Phase 1 | Completed | Healthy Male Subjects | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07367958) |
| October 1, 2025 | NCT07200986 | Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects | Celltrion | Phase 1 | Active not recruiting | Healthy Participants | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200986) |
| September 5, 2025 | NCT07158346 | Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in... | Celltrion | Phase 1 | Completed | Type 2 Diabetes Mellitus (T2DM) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07158346) |
| August 19, 2025 | NCT07128654 | A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers | Celltrion | Phase 1 | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128654) |
| July 30, 2025 | NCT07093476 | Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin | Celltrion | Phase 3 | Recruiting | T2DM, Diabete Type 2, DM | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07093476) |
| July 8, 2025 | NCT07054970 | To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects | Celltrion | Phase 1 | Completed | Healthy Male Subjects | 172 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07054970) |
| May 1, 2025 | NCT06952478 | A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and... | Celltrion | Phase 3 | Active not recruiting | Refractory or Relapsed Multiple Myeloma | 473 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952478) |
| April 30, 2025 | NCT06951828 | A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects | Celltrion | Phase 1 | Completed | Healthy Male Subjects | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06951828) |
| April 23, 2025 | NCT06939595 | A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | Celltrion | Phase 3 | Active not recruiting | Non Squamous Non Small Cell Lung Cancer | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06939595) |
| December 18, 2024 | NCT06738719 | A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients With Moderate to Severe Active Rheumatoid Arthritis | Celltrion | Phase 3 | Completed | Moderately to Severely Active Rheumatoid Arthritis | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06738719) |
| November 14, 2024 | NCT06687928 | To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab) | Celltrion | Phase 1 | Completed | Healthy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687928) |
| October 8, 2024 | NCT06630559 | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis | Celltrion | Phase 3 | Active not recruiting | Plaque Psoriasis | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06630559) |
| August 26, 2024 | NCT06571591 | Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin | Celltrion | Phase 3 | Completed | T2DM | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06571591) |
| September 14, 2023 | NCT06037395 | Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects | Celltrion | Phase 1 | Completed | Healthy Subject | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06037395) |
| August 15, 2023 | NCT05993806 | A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers | Celltrion | Phase 1 | Completed | Essential Hypertension | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05993806) |
| June 18, 2023 | NCT05906992 | A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting... | Celltrion | Phase 3 | Recruiting | Relapsing-remitting Multiple Sclerosis | 512 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05906992) |
| May 19, 2023 | NCT05866614 | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps | Celltrion | Observational | Active not recruiting | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis | 881 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05866614) |
| February 13, 2023 | NCT05725434 | A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis | Celltrion | Phase 3 | Unknown | Rheumatoid Arthritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05725434) |
| November 15, 2022 | NCT05617183 | Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects | Celltrion | Phase 1 | Unknown | Healthy Subjects | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05617183) |
| October 14, 2022 | NCT05581693 | A Bioequivalence Study of L04TD2 Compared to Administration of L04RD1 in Healthy Volunteers | Celltrion | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05581693) |
| October 5, 2022 | NCT05568121 | A Bioequivalence Study of L04TD1 Compared to Administration of L04RD1 in Healthy Volunteers | Celltrion | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05568121) |
| August 10, 2022 | NCT05495568 | To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis | Celltrion | Phase 3 | Completed | Moderate to Severe Chronic Plaque Psoriasis | 367 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05495568) |
| August 5, 2022 | NCT05489224 | A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis | Celltrion | Phase 3 | Completed | Rheumatoid Arthritis | 471 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05489224) |
| May 23, 2022 | NCT05385770 | Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects | Celltrion | Phase 3 | Completed | Essential Hypertension | 890 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05385770) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 38 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 31 |
| Observational | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 60 |
| Terminated | 6 |
| Active not recruiting | 5 |
| Unknown | 3 |
| Recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 13 |
| COVID-19 | 5 |
| Crohn Disease | 4 |
| Spondylitis, Ankylosing | 4 |
| Colitis, Ulcerative | 3 |
| Diabetes Mellitus, Type 2 | 3 |
| Psoriasis | 2 |
| Lymphoma, Follicular | 2 |
| Breast Neoplasms | 2 |
| Essential Hypertension | 2 |
| Lymphoma, Large B-Cell, Diffuse | 1 |
| Adenocarcinoma of Lung | 1 |
| Arthritis, Psoriatic | 1 |
| Chronic Urticaria | 1 |
| Cardiomyopathy, Hypertrophic | 1 |
| Multiple Myeloma | 1 |
| Multiple Sclerosis, Relapsing-Remitting | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Middle schools in the United States](https://specstream.ai/data/businesses/middle-schools/united-states)
- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
- [B2B oil and gas companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-companies/united-states)
- [Tires manufacturers in the United States](https://specstream.ai/data/businesses/tires-manufacturers/united-states)
